Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Schlumberger MJ, et al. Among authors: droz jp. J Clin Oncol. 2009 Aug 10;27(23):3794-801. doi: 10.1200/JCO.2008.18.7815. Epub 2009 Jun 29. J Clin Oncol. 2009. PMID: 19564535 Clinical Trial.
Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Sherman SI, et al. Among authors: droz jp. N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853. N Engl J Med. 2008. PMID: 18596272 Free article. Clinical Trial.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. Among authors: droz jp. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S, et al. Among authors: droz jp. J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461. J Clin Oncol. 2008. PMID: 18202419 Clinical Trial.
Targeted therapies and thyroid cancer: an update.
de la Fouchardiere C, Droz JP. de la Fouchardiere C, et al. Among authors: droz jp. Anticancer Drugs. 2011 Aug;22(7):688-99. doi: 10.1097/CAD.0b013e32834319c7. Anticancer Drugs. 2011. PMID: 21200314 Review.
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Derbel Miled O, Dionne C, Terret C, Segura-Ferlay C, Flechon A, Neidhart EM, Negrier S, Droz JP. Derbel Miled O, et al. Among authors: droz jp. J Geriatr Oncol. 2013 Jul;4(3):255-61. doi: 10.1016/j.jgo.2013.04.004. Epub 2013 May 9. J Geriatr Oncol. 2013. PMID: 24070463
Pleural metastasis in a patient with bladder cancer.
Bonnin N, El Karak F, Droz JP, Flechon A. Bonnin N, et al. Among authors: droz jp. J Clin Oncol. 2008 Jan 10;26(2):329-30. doi: 10.1200/JCO.2007.13.9865. J Clin Oncol. 2008. PMID: 18182674 No abstract available.
470 results